GLP-1 Agonist Peptides
Activates GLP-1 receptors
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of peptides that mimic the incretin hormone GLP-1, which your gut naturally releases after eating. They have become the most impactful class of peptides in modern medicine, with FDA-approved drugs generating over $50 billion in annual revenue. Semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide (Victoza/Saxenda) are the major approved compounds. Retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors) is in late-stage clinical trials.
These peptides simultaneously address weight loss, blood sugar control, cardiovascular risk, and potentially liver disease and kidney disease. Clinical trials have shown cardiovascular mortality reduction, fatty liver improvement, and even potential benefits for Alzheimer's disease and addiction. Their broad metabolic effects make them relevant far beyond their original indication of type 2 diabetes.
This page collects every GLP-1 receptor agonist on PeptideWiki. Browse individual profiles for specific mechanisms, dosing, and clinical trial data.
Peptides (3)
Semaglutide
Semaglutide is a medication that mimics a natural fullness hormone (GLP-1) in the body. It is FDA-approved as Wegovy for weight management and Ozempic for type 2 diabetes, with significant effects on appetite control and blood sugar regulation.
Tirzepatide
Tirzepatide is a dual-action medication that activates both GIP and GLP-1 receptors, two key fullness and blood sugar hormones. It is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management, outperforming semaglutide in head-to-head trials.
Liraglutide
Liraglutide is a medication that mimics a natural fullness hormone (GLP-1) in the body. It is FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management, with an extensive record of clinical safety and effectiveness data.